These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 26957557)

  • 1. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.
    Goldinger SM; Stieger P; Meier B; Micaletto S; Contassot E; French LE; Dummer R
    Clin Cancer Res; 2016 Aug; 22(16):4023-9. PubMed ID: 26957557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
    Shi VJ; Rodic N; Gettinger S; Leventhal JS; Neckman JP; Girardi M; Bosenberg M; Choi JN
    JAMA Dermatol; 2016 Oct; 152(10):1128-1136. PubMed ID: 27411054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
    Vivar KL; Deschaine M; Messina J; Divine JM; Rabionet A; Patel N; Harrington MA; Seminario-Vidal L
    J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.
    Schaberg KB; Novoa RA; Wakelee HA; Kim J; Cheung C; Srinivas S; Kwong BY
    J Cutan Pathol; 2016 Apr; 43(4):339-46. PubMed ID: 26762844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management.
    Hwang SJ; Anforth R; Carlos G; Fernandez-Peñas P
    Actas Dermosifiliogr; 2017; 108(1):6-16. PubMed ID: 27642030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.
    Chou S; Hwang SJ; Carlos G; Wakade D; Fernandez-Penas P
    Am J Dermatopathol; 2017 Jan; 39(1):23-27. PubMed ID: 28045749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
    Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
    Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dermatologic toxicities of immune checkpoint inhibitors].
    Sibaud V; Boulinguez S; Pagès C; Riffaud L; Lamant L; Chira C; Boyrie S; Vigarios E; Tournier E; Meyer N
    Ann Dermatol Venereol; 2018 May; 145(5):313-330. PubMed ID: 29678394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases.
    Wakade DV; Carlos G; Hwang SJ; Chou S; Hui R; Fernandez-Peñas P
    Melanoma Res; 2016 Aug; 26(4):421-4. PubMed ID: 27135655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor-related dermatologic adverse events.
    Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
    J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
    Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
    Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.